The clinical significance of transforming acidic coiled-coil protein 3 expression in XXXX .

@entity29189 @entity1 @entity4166 @entity1149 @entity2
UNASSIGNED: The relationship between @entity29189 , a member of the transforming acidic coiled-coil proteins (TACCs) family, and @entity2 remains unclear. The present study was designed to explore the prognostic and clinical significance of @entity29189 in @entity1149 ( @entity1149 ). An immunohistochemistry (IHC) assay was performed to analyze the expression of @entity29189 in 195 @entity2 cases. The mRNA and protein levels of @entity29189 were examined by quantitative reverse transcription-PCR or western blotting. The correlation between @entity29189 expression and clinicopathological factors was analyzed by   2 analysis and Fisher's exact test. Kaplan  -Meier analysis and the Cox proportional hazards model were used to examine the correlation of prognostic outcomes with @entity29189 . The results showed that the levels of @entity29189 mRNA and total protein were higher in @entity2 lesions than paired non-cancerous tissues. IHC analysis revealed that @entity29189 was highly expressed in 94 (48.2%) cases. The expression of @entity29189 was strongly correlated with smoking status, histological classification, differentiation, @entity4166 fragment levels, T stage and the clinical stage of @entity1149  @entity1 . Univariate and multivariate analyses demonstrated that @entity29189 is a useful biomarker for @entity1149 prognosis. The low @entity29189 expression group exhibited better progression-free survival (PFS) among  @entity1 who received anti-microtubule chemotherapy. In conclusion, the results showed that a high level of @entity29189 expression was correlated with advanced clinicopathological classifications, poor overall survival (OS) and poor recurrence  -free survival (RFS) in @entity1149  @entity1 . Our findings indicate that @entity29189 is a potential prognostic marker and therapeutic target for @entity1149 .
